Permethrin-treated mosquito nets and the EU BPR regulatory calendar: what 2026-2028 means for the treated-article category

If you are a European buyer trying to understand what is happening with permethrin-treated mosquito nets under EU rules - whether the category is being phased out, whether authorisations are about to lapse, whether "candidate for substitution" means a product recall - this article is the calendar and the trust-signal reference. It consolidates the operational regulatory tracking Mosticare runs against the Biocidal Products Regulation (BPR, Regulation (EU) 528/2012) and ECHA's Biocidal Products Committee (BPC) for the treated-article permethrin family only.

It is not about Mosticare's untreated mosquito nets - the Terrazza gazebo, the baby and crib canopies, and the bed and travel nets sold under the rest of the catalogue. Those are physical barriers, not biocidal products, and the BPR does not regulate them. None of the BPR claims or calendar entries in this article apply to those SKUs, and Mosticare does not extend them by reference. Every claim about permethrin, EU BPR authorisation, or WHO prequalification below is scoped to the thirteen treated SKUs in Mosticare's permethrin-treated range.

This is a trust-signal maintenance piece. It is published as a standing reference inside the editorial canon so that the dates, the authorisation record, and the regulator language are stable and verifiable across all of Mosticare's markets. It will be re-published at each material change.

What this article is, and what it is not

This article is a regulatory calendar for the thirteen treated SKUs in the Mosticare permethrin range. It records the EU product authorisation in force, the active-substance review window that surrounds it, and the BPR events the editorial and product teams track for the 2026-2028 window.

This article is not a medical claim, an efficacy comparison with repellent alternatives, a regulatory guarantee, or a coverage statement for the rest of the Mosticare catalogue. The Mosticare Terrazza gazebo, the baby and crib canopies, and the untreated bed nets are outside the scope of BPR and are not addressed in this piece. No GOTS or OEKO-TEX claim is made or implied in relation to any treated net, the untreated physical barriers, or the broader catalogue. No partnership or endorsement by any research institute is claimed.

The headline facts about Mosticare's treated-article range

The authority number, treated-SKU coverage, and 2032 validity appear consistently across the thirteen treated-SKU description files, the product registry, and the mosticare.org treated-net product pages. The article-58 family structure is documented in Mosticare's regulatory file and supported by the corresponding summary in the EU BPR register.

How to read the BPR in this product context

The BPR is the EU regulation that governs biocidal products and the active substances they contain. Two of its 22 defined product types are relevant to mosquito control:

• PT18 - Insecticides, acaricides and products to control other arthropods. Treated mosquito nets fall here. They kill mosquitoes that contact the treated surface. The active substance - permethrin, in Mosticare's case - must be approved at EU level, and the finished product must be authorised under Article 58 of the BPR (treated articles) or under a national Union authorisation.
• PT19 - Repellents and attractants. Skin-applied repellents fall here. They do not apply to treated nets.

The BPR runs on three separate clocks that operate at different layers and that are often confused in consumer coverage:

1. The active-substance clock - the EU-level approval of permethrin as an active substance for PT18. This is the rolling 2026-2027 pyrethroid review programme at ECHA. The non-approval extension for permethrin runs through October 2028.
2. The product authorisation clock - Mosticare's specific authorisation EU-0026815-0000, which covers the thirteen treated SKUs. Validity through 2032.
3. The treated-article clock - Article 58 requires the treated article's label and Summary of Product Characteristics (SPC) to match the authorised wording. Label deviation is an immediate market-surveillance risk and operates continuously; it is not a calendar event.

The three clocks intersect: if the active-substance clock fails (permethrin approval lapses or is not renewed at EU level), all permethrin products including Mosticare's lose EU market access. If the product authorisation clock fails (the 2032 renewal is mishandled), Mosticare's specific SKUs lose EU market access. If the treated-article clock fails (label drifts away from the SPC), a market-surveillance finding can withdraw product from sale irrespective of either of the other clocks.

Mosticare's standing position is that all three clocks are tracked and that the article-58 label is the most immediate compliance lever for the 2026-2027 window.

The 2026-2028 calendar for the treated permethrin family

The table below lists the BPR events Mosticare tracks for the thirteen treated SKUs. It is the operational calendar that drives the regulatory watch and the editorial calendar for the treated-net category. Items marked watching are not Mosticare-specific actions; items marked internal action are Mosticare-led; items marked regulator action are ECHA-, BPC- or Commission-led.

The standing editorial position is that the 2026-2028 window is calm for the Mosticare treated range, with the active-substance review programme being the main external variable. The renewal cycle for EU-0026815-0000 itself does not begin until late 2027 / early 2028, and the substantive dossier is not due until early 2030. There is no near-term expiry, no phase-out, and no in-force market-withdrawal action affecting the thirteen treated SKUs.

What "Candidate for Substitution" means, and what it does not mean

Permethrin appears on ECHA's list of Candidates for Substitution under BPR Article 10(1). The label is regulator language and has a specific technical meaning:

• What it is. Article 10(1) flags active substances that meet certain criteria - for example, substances that are persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB), or that have other intrinsic properties of concern at EU level. The flag is a procedural note attached to the substance's approval conditions; it is not a recall, a phase-out, or a market action.
• What it triggers. When a product containing a Candidate-for-Substitution active substance comes up for authorisation or renewal, the evaluating competent authority performs a comparative assessment and considers whether the product can be replaced by an already-authorised product or a non-chemical alternative. The substitution analysis is part of the normal authorisation cycle, not an ad-hoc withdrawal.
• What it does not trigger. Candidate-for-Substitution status does not require existing products to be withdrawn, does not shorten the validity of an existing product authorisation, and does not override a Member State or Union-level authorisation that is already in force. EU-0026815-0000 is in force through 2032 on its published terms, with the Candidate-for-Substitution flag tracked inside the renewal evaluation when it occurs.
• What the consumer-facing consequence is. None, in the short term. The product label, the user instructions, and the protective function of the net are unchanged. The flag becomes editorially relevant when the renewal evaluation cycle runs in 2027-2028, and it will be reported in the renewal-procedure update published in this article at that time.

The Candidate-for-Substitution flag is part of the public record for permethrin and is not a Mosticare-specific finding. It applies to the active substance and to every product containing it on the EU market, not to Mosticare's treated range uniquely.

What WHO prequalification means for the treated range, and how Mosticare uses the label

The World Health Organization Prequalification Programme for Vector Control Products evaluates long-lasting insecticidal nets (LLINs), indoor residual sprays, and similar vector-control products against WHO specifications. WHO prequalification is a separate regulatory track from EU BPR - a product can be WHO-prequalified without being BPR-authorised, and BPR-authorised without being WHO-prequalified.

Mosticare's treated permethrin range is:

• EU BPR authorised under EU-0026815-0000 (PT18 / Article 58 treated article). This is the EU regulatory record.
• Built to WHO vector-control product specifications (LLIN standard, 9 g/kg factory impregnation). This is an engineering compliance statement - the construction of the net follows the WHO specification, not an efficacy claim of WHO prequalification.
• Not separately WHO-prequalified. Mosticare does not hold a WHO Prequalification Programme listing for the thirteen treated SKUs. Where Mosticare copy refers to WHO standards, it means the WHO specification was the engineering reference, not that the product is on the WHO prequalification list.

The distinction is editorial, not technical: the buyer reading a Mosticare product page should understand that "built to WHO standards" and "WHO prequalified" are not the same statement. The first is an engineering reference; the second is a regulator listing. Mosticare's editorial canon uses the first and not the second.

The same distinction applies to the ECHA register. "EU BPR authorised" means the product appears in ECHA's R4BP 3 register under the authorisation number. It does not mean "endorsed by ECHA" or "approved by ECHA as a product" - those formulations are not used in Mosticare copy.

What the buyer should take from this article

Three operational takeaways:

1. The thirteen treated SKUs are covered by a current EU BPR authorisation (EU-0026815-0000) that runs through 2032. There is no in-force market action affecting them, no current withdrawal, and no near-term expiry for Mosticare's product authorisation.
2. The active-substance layer is the standing watch. Permethrin is in ECHA's rolling 2026-2027 pyrethroid review programme; the current non-approval extension runs to October 2028. The renewal outcome affects every permethrin PT18 product on the EU market, not just Mosticare's, and Mosticare's editorial calendar reflects that external dependency.
3. The treated-article label is the most immediate internal lever. Mosticare's editorial and product teams verify, on every translation cycle and every product-page edit, that the wording matches the authorised SPC. Drift away from the SPC is the failure mode that produces a market-surveillance finding irrespective of the other two clocks. Buyer-facing copy in this article and on the treated-net product pages is held to that SPC.

A fourth, standing editorial note: the rest of the Mosticare catalogue is not addressed by this article. The Terrazza gazebo, the baby and crib canopies, and the untreated bed and travel nets are physical barriers. They are not biocidal products. EU BPR authorisation, permethrin, WHO prequalification, and the ECHA pyrethroid review programme do not apply to them. They are not addressed by this article and are not extended by reference. No GOTS or OEKO-TEX certification is claimed for any treated net, for any untreated net, or for the broader catalogue. No partnership or endorsement by any research institute is claimed.

When this article will be updated

The standing rule is that this article is republished at each of the following triggers:

• ECHA BPC opinion or decision on the permethrin PT18 review programme.
• Commission Implementing Act or SCBP vote touching permethrin, treated articles, or PT18.
• Material change to EU-0026815-0000 - renewal procedure start, dossier filing, or expiry update.
• Material change to the Candidate-for-Substitution status for permethrin under BPR Article 10(1).
• Material change to the WHO Prequalification Programme listing for permethrin-treated nets that affects Mosticare's treated-SKU range.
• Material change to the mosticare.org treated-net product pages that introduces, removes, or modifies a BPR-related, WHO-related, or permethrin-related claim.

Editorial updates are logged in the issue trail under Mosticare's content pipeline and announced on the editorial calendar. The article is the canonical reference for the treated-article calendar across the four Mosticare markets (France, Germany-Austria-Switzerland, Italy, and English-speaking Europe).

Sources

• European Chemicals Agency (ECHA). Biocidal Products Regulation portal and R4BP 3 register. Authorisation EU-0026815-0000 - treated-article family under Article 58 (PT18).
• European Commission. Regulation (EU) No 528/2012 - Biocidal Products Regulation (BPR). Articles 10, 17, 58, 69 and 72 cited in the body.
• European Commission. Commission proposal of 16 December 2025 amending BPR to extend data protection periods until 31 December 2030. Sent to the European Parliament and Council.
• European Chemicals Agency. Biocidal Products Committee (BPC) opinion register. Pyrethroid PT18 review programme, 2026-2027 cycle.
• European Chemicals Agency. Candidates for Substitution under BPR Article 10(1). Current permethrin entry.
• World Health Organization. Vector Control Product Prequalification Programme. LLIN specifications referenced; no Mosticare listing.
• Mosticare product registry (internal). SKU coverage, factory impregnation rate, target species, EU BPR authorisation reference.
• Mosticare regulatory file (internal). EU-0026815-0000 - treated-article family scope, SPC, label.
• Mosticare Editorial - internal claims canon. Used for the treated-only scoping, the WHO/BPR wording discipline, and the no-GOTS / no-OEKO-TEX / no-institute-endorsement guardrails in this article.